News + Resources
Keep up with the latest
Featured
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
CRISPR 2.0, the Next Generation
June 21, 2024
Aspen Ideas: Health
CRISPR 2.0, the Next Generation
June 21, 2024
All Stories
Press Release
Scribe Therapeutics to Participate in Upcoming Goldman Sachs The New Guard: Privates Leading the Disruption in Healthcare Investor Conference
April 1, 2022
Read Now
Press Release
Scribe Therapeutics to Participate in Upcoming Goldman Sachs The New Guard: Privates Leading the Disruption in Healthcare Investor Conference
April 1, 2022
Read Now
News
CRISPR pioneer's biotech taps ex-Barclays banker as CFO
March 21, 2022
CFO Dive
Read Now
Press Release
CRISPR pioneer's biotech taps ex-Barclays banker as CFO
March 21, 2022
CFO Dive
Read Now
News
Peer Review
March 11, 2022
Endpoints News
Read Now
Press Release
Peer Review
March 11, 2022
Endpoints News
Read Now